VHCP Management II’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

VHCP Management II’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-677,164	Closed	-$16M	–	28
2019 Q3	$16M	Hold	677,164	–	–	6.1%	7
2019 Q2	$20.4M	Buy	677,164 +44,684	+7%	+$1.02M	6.42%	6
2019 Q1	$14.2M	Hold	632,480	–	–	4.15%	9
2018 Q4	$11.5M	Buy	632,480 +87,868	+16%	+$1.38M	4.94%	9
2018 Q3	$9.85M	Hold	544,612	–	–	2.63%	11
2018 Q2	$5.42M	Hold	544,612	–	–	1.62%	15
2018 Q1	$2.89M	Hold	544,612	–	–	0.7%	16
2017 Q4	$4.63M	Sell	544,612 -225,159	-29%	-$2.77M	1.11%	14
2017 Q3	$11.2M	Hold	769,771	–	–	3.11%	11
2017 Q2	$14.4M	Buy	769,771 +44,742	+6%	+$1.01M	5.76%	6
2017 Q1	$15.4M	Buy	725,029 +182,529	+34%	+$3.49M	6.32%	6
2016 Q4	$8.24M	Buy	+542,500	New	+$7.37M	3.95%	7

Other funds holding RARX

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VHCP Management II's RARX Position: Q4 2019 in Review

VHCP Management II sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q4 2019, closing a stake of 677,164 shares — an estimated $16M sold.

VHCP Management II first reported a position in RARX in Q4 2016 and held it in 12 quarters. The position peaked at $20.4M in Q2 2019. 146 funds tracked by Wall St. Rank hold RARX as of Q4 2019.

VHCP Management II reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
VHCP Management II sold 677,164 Ra Pharmaceuticals, Inc. Common Stock shares in Q4 2019, an estimated $16M.
VHCP Management II first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2016 and held it in 12 quarters.
VHCP Management II's Ra Pharmaceuticals, Inc. Common Stock position peaked at $20.4M in Q2 2019.
146 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q4 2019.

Based on VHCP Management II's 13F filing for Q4 2019, filed 13 Feb 2020.